CIK 0001604464 · Non-accelerated filer<br>Smaller reporting company
Atara Biotherapeutics, Inc.
Sign in to watch- Ticker
- ATRA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 460920988
- Phone
- 805-623-4211
- Business address
- 1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA, 91320
- 4 Grant or award EVP, Global Head RA & Quality acquired 450,000 shares (grant or award)
- 424B5 Offering Prospectus
- SC 13G/A Stake Amended Statement of Ownership
- 8-K Event Material agreement · Delisting notice
- 8-K Event Exit or restructuring costs · Executive or director change · Regulation FD disclosure · Other events
- S-8 Other Securities Offered to Employees in Benefit Plans
- 8-K Event Other events
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G Stake Amended Statement of Ownership
- 4 Open-market sale President and CEO sold 20,409 shares at $0.39 ($7,939)
- 4 Open-market sale EVP, Chief Sci. & Tech Officer sold 8,856 shares at $0.39 ($3,445)
- 4 Open-market sale EVP, Chief Legal Officer sold 8,307 shares at $0.39 ($3,231)
- 4 Open-market sale EVP, Chief Medical Officer sold 12,287 shares at $0.39 ($4,780)
- 4 Open-market sale SVP, CFO sold 11,958 shares at $0.39 ($4,652)
- 4 Open-market sale EVP, Global Head RA & Quality sold 3,267 shares at $0.39 ($1,271)
- 424B3 Offering Prospectus
- 4 Open-market buy Director bought 270,000 shares at an average $0.25 ($68,214)
- 4 Open-market buy Director bought 100,000 shares at $0.25 ($25,330)
- 4 Open-market buy Director bought 446,825 shares at $0.23 ($101,340)
- EFFECT Other Notice of Effectiveness
Page 12 of 57 · 1,133 filings